Leptomeningeal Metastatic L858R <i>EGFR</i>-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib

Leptomeningeal Metastatic L858R <i>EGFR</i>-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib

<p dir="ltr">Leptomeningeal carcinomatosis (LMC) is a known sequel of metastatic lung cancer and its treatment is challenging. Nevertheless, treatment options for LMC due to metastatic epidermal growth factor receptor-mutant (EGFR-mutant) lung adenocarcinoma are expanding. We present...

Full description

Saved in:
Bibliographic Details
Main Author: Aladdin Kanbour (14442123) (author)
Other Authors: Faroug Salih (21323705) (author), Wafa Abualainin (14442141) (author), Mohamed Abdelrazek (6903689) (author), Lajos Szabados (16561323) (author), Issam Al-Bozom (4711098) (author), Nabil E Omar (18093844) (author)
Published: 2022
Subjects:
Biomedical and clinical sciences
Neurosciences
Oncology and carcinogenesis
NSCLC
non-small-cell lung cancer
LMC
leptomeningeal carcinomatosis
EGFR
epidermal growth factor receptor
EGFR-TKIs
EGFR tyrosine kinase inhibitors
osimertinib
pulsed erlotinib
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items